NL8202810A - Spasmolytisch werkzaam (+)-secoverine. - Google Patents

Spasmolytisch werkzaam (+)-secoverine. Download PDF

Info

Publication number: NL8202810A
Authority: NL; Netherlands
Prior art keywords: secoverine; butanone; cyclohexyl; salt; compound
Prior art date: 1982-07-12

Application number

NL8202810A

Other languages

English (en)

Dutch (nl)

Original Assignee

Duphar Int Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-07-12

Filing date

1982-07-12

Publication date

1984-02-01

1982-07-12 Application filed by Duphar Int Res filed Critical Duphar Int Res

1982-07-12 Priority to NL8202810A priority Critical patent/NL8202810A/nl

1983-07-04 Priority to DE8383200987T priority patent/DE3363919D1/de

1983-07-04 Priority to EP83200987A priority patent/EP0100569B1/en

1983-07-04 Priority to AT83200987T priority patent/ATE20230T1/de

1983-07-07 Priority to ZA834981A priority patent/ZA834981B/xx

1983-07-07 Priority to AU16630/83A priority patent/AU562820B2/en

1983-07-08 Priority to ES523978A priority patent/ES8404182A1/es

1983-07-08 Priority to DK316783A priority patent/DK316783A/da

1983-07-08 Priority to GR71891A priority patent/GR78645B/el

1983-07-08 Priority to PH29196A priority patent/PH22077A/en

1983-07-08 Priority to IL69187A priority patent/IL69187A/xx

1983-07-11 Priority to JP58124895A priority patent/JPS5931741A/ja

1983-07-11 Priority to CA000432186A priority patent/CA1218076A/en

1984-02-01 Publication of NL8202810A publication Critical patent/NL8202810A/nl

Links

229950004117 secoverine Drugs 0.000 title abstract description 27
230000002048 spasmolytic effect Effects 0.000 title description 8
239000000812 cholinergic antagonist Substances 0.000 title description 3
150000003839 salts Chemical class 0.000 claims abstract description 10
238000002360 preparation method Methods 0.000 claims abstract description 7
150000001875 compounds Chemical class 0.000 claims description 13
238000000034 method Methods 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 6
239000000825 pharmaceutical preparation Substances 0.000 claims description 3
UZJXIUHXVNHUJC-UHFFFAOYSA-N 4-chloro-1-cyclohexylbutan-1-one Chemical compound ClCCCC(=O)C1CCCCC1 UZJXIUHXVNHUJC-UHFFFAOYSA-N 0.000 claims description 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
239000005977 Ethylene Substances 0.000 claims description 2
208000007101 Muscle Cramp Diseases 0.000 claims description 2
208000005392 Spasm Diseases 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 14
WAVYHSURRZBQKO-UHFFFAOYSA-N 1-cyclohexyl-4-[ethyl-[1-(4-methoxyphenyl)propan-2-yl]amino]butan-1-one Chemical compound C=1C=C(OC)C=CC=1CC(C)N(CC)CCCC(=O)C1CCCCC1 WAVYHSURRZBQKO-UHFFFAOYSA-N 0.000 abstract description 5
239000008194 pharmaceutical composition Substances 0.000 abstract 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
229960002748 norepinephrine Drugs 0.000 description 7
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
239000003506 spasmogen Substances 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
230000003444 anaesthetic effect Effects 0.000 description 4
230000008602 contraction Effects 0.000 description 4
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000003556 assay Methods 0.000 description 3
AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 3
229960004484 carbachol Drugs 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
HEDXEAAVEOJUCR-UHFFFAOYSA-N furtrethonium Chemical compound C[N+](C)(C)CC1=CC=CO1 HEDXEAAVEOJUCR-UHFFFAOYSA-N 0.000 description 3
229950008234 furtrethonium Drugs 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000003589 local anesthetic agent Substances 0.000 description 3
230000002093 peripheral effect Effects 0.000 description 3
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
210000001630 jejunum Anatomy 0.000 description 2
239000000203 mixture Substances 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000126 substance Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
241000947840 Alteromonadales Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
210000003405 ileum Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002690 local anesthesia Methods 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
230000003033 spasmogenic effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
External Artificial Organs (AREA)

NL8202810A 1982-07-12 1982-07-12 Spasmolytisch werkzaam (+)-secoverine. NL8202810A (nl)

Priority Applications (13)

Application Number	Priority Date	Filing Date	Title
NL8202810A NL8202810A (nl)	1982-07-12	1982-07-12	Spasmolytisch werkzaam (+)-secoverine.
DE8383200987T DE3363919D1 (en)	1982-07-12	1983-07-04	Spasmolytically active (+)s-enantiomer of secoverine
EP83200987A EP0100569B1 (en)	1982-07-12	1983-07-04	Spasmolytically active (+)s-enantiomer of secoverine
AT83200987T ATE20230T1 (de)	1982-07-12	1983-07-04	Spasmolytisch wirksames (+)s-enantiomer von secoverin.
ZA834981A ZA834981B (en)	1982-07-12	1983-07-07	Spasmolytically active(+)s-enantiomer of secoverine
AU16630/83A AU562820B2 (en)	1982-07-12	1983-07-07	(+)s-enantiomer of secoverline
ES523978A ES8404182A1 (es)	1982-07-12	1983-07-08	Un metodo de prepara el enantiomero (+) s de secoverin
DK316783A DK316783A (da)	1982-07-12	1983-07-08	Spasmolytisk aktiv (+)-s-enantiomer af secoverin, fremgangsmaade til dens fremstilling samt dens anvendelse
GR71891A GR78645B (da)	1982-07-12	1983-07-08
PH29196A PH22077A (en)	1982-07-12	1983-07-08	Spasmolytically active (+) s enantiomer of secoverine
IL69187A IL69187A (en)	1982-07-12	1983-07-08	(+)-s-secoverine and salts thereof,their preparation and pharmaceutical compositions containing them
JP58124895A JPS5931741A (ja)	1982-07-12	1983-07-11	セコベリンの（＋）ｓ鏡像異性体およびその塩、その製造方法並びにこの化合物を含有する鎮痙剤
CA000432186A CA1218076A (en)	1982-07-12	1983-07-11	Spasmolytically active ( )s-enantiomer of secoverine

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
NL8202810		1982-07-12
NL8202810A NL8202810A (nl)	1982-07-12	1982-07-12	Spasmolytisch werkzaam (+)-secoverine.

Publications (1)

Publication Number	Publication Date
NL8202810A true NL8202810A (nl)	1984-02-01

Family

ID=19840015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8202810A NL8202810A (nl)	1982-07-12	1982-07-12	Spasmolytisch werkzaam (+)-secoverine.

Country Status (13)

Country	Link
EP (1)	EP0100569B1 (da)
JP (1)	JPS5931741A (da)
AT (1)	ATE20230T1 (da)
AU (1)	AU562820B2 (da)
CA (1)	CA1218076A (da)
DE (1)	DE3363919D1 (da)
DK (1)	DK316783A (da)
ES (1)	ES8404182A1 (da)
GR (1)	GR78645B (da)
IL (1)	IL69187A (da)
NL (1)	NL8202810A (da)
PH (1)	PH22077A (da)
ZA (1)	ZA834981B (da)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL8700842A (da) *	1987-04-10	1988-11-01	Duphar Int Res
JPH06508836A (ja) *	1991-06-26	1994-10-06	セプラコア，インコーポレーテッド	光学的に純粋なｒ（＋）オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
EP1013275A3 (en) *	1991-11-26	2001-01-10	Sepracor, Inc.	Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
US6548082B1 (en)	1999-03-01	2003-04-15	Sepracor Inc.	Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4125623A (en) *	1974-04-08	1978-11-14	U.S. Philips Corporation	Spasmolytics

1982
- 1982-07-12 NL NL8202810A patent/NL8202810A/nl not_active Application Discontinuation
1983
- 1983-07-04 DE DE8383200987T patent/DE3363919D1/de not_active Expired
- 1983-07-04 EP EP83200987A patent/EP0100569B1/en not_active Expired
- 1983-07-04 AT AT83200987T patent/ATE20230T1/de not_active IP Right Cessation
- 1983-07-07 ZA ZA834981A patent/ZA834981B/xx unknown
- 1983-07-07 AU AU16630/83A patent/AU562820B2/en not_active Ceased
- 1983-07-08 DK DK316783A patent/DK316783A/da not_active Application Discontinuation
- 1983-07-08 PH PH29196A patent/PH22077A/en unknown
- 1983-07-08 IL IL69187A patent/IL69187A/xx unknown
- 1983-07-08 GR GR71891A patent/GR78645B/el unknown
- 1983-07-08 ES ES523978A patent/ES8404182A1/es not_active Expired
- 1983-07-11 CA CA000432186A patent/CA1218076A/en not_active Expired
- 1983-07-11 JP JP58124895A patent/JPS5931741A/ja active Pending

Also Published As

Publication number	Publication date
ATE20230T1 (de)	1986-06-15
PH22077A (en)	1988-05-20
DE3363919D1 (en)	1986-07-10
CA1218076A (en)	1987-02-17
AU562820B2 (en)	1987-06-18
GR78645B (da)	1984-09-27
ES523978A0 (es)	1984-04-16
ZA834981B (en)	1984-03-28
EP0100569B1 (en)	1986-06-04
ES8404182A1 (es)	1984-04-16
DK316783A (da)	1984-01-13
IL69187A (en)	1986-08-31
IL69187A0 (en)	1983-11-30
DK316783D0 (da)	1983-07-08
JPS5931741A (ja)	1984-02-20
AU1663083A (en)	1984-01-19
EP0100569A1 (en)	1984-02-15

Legal Events

Date	Code	Title
1984-02-01	A1B	A search report has been drawn up
1985-01-01	A85	Still pending on 85-01-01
1985-03-01	BV	The patent application has lapsed

Publication	Publication Date	Title
EP0125783B1 (en)	1989-01-04	Dopamine-beta-hydroxylase inhibitors
CZ99698A3 (cs)	1998-08-12	Heterocyklické deriváty s indolinovým, indolovým nebo tetrahydrochinolinovým cyklem a jejich farmaceutické použití
CZ398191A3 (en)	1993-02-17	Novel 4-amino alkyl-2(3h)-indolones and pharmaceutical compositions containing them
JPWO1994014769A1 (ja)	1995-02-02	Ｎ−置換インドール誘導体
EP0752988A1 (fr)	1997-01-15	DERIVES DE 5H-INDENO[1,2-b]PYRAZINE-2,3-DIONE, LEUR PREPARATION ET LES MEDICAMENTS LES CONTENANT
PT85799B (pt)	1990-08-31	Processo para a preparacao de fenilalquilaminas e de composicoes farmaceuticas contendo-as
FI92053C (fi)	1994-09-26	Analogiamenetelmä uuden lääkkeen valmistamiseksi
EP0110781A1 (fr)	1984-06-13	(Amino-2 éthyl)-6 benzoxazolinones substituées, leur préparation et une composition pharmaceutique les contenant
LU85747A1 (fr)	1986-08-04	Derives d'imidazole leur preparation et utilisation ainsi que les compositions pharmaceutiques contenant des derives
EP0482183B1 (fr)	1997-07-30	Composes agonistes du recepteur h3 de l'histamine a usage therapeutique, compositions pharmaceutiques agissant comme agonistes dudit recepteur et procede de preparation
FR2726275A1 (fr)	1996-05-03	Spiro heterocycle-imidazo(1,2-a)indeno(1,2-e)pyrazine)-4'- ones, leur preparation et les medicaments les contenants
US4425336A (en)	1984-01-10	3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
NL8202810A (nl)	1984-02-01	Spasmolytisch werkzaam (+)-secoverine.
JPS59176284A (ja)	1984-10-05	８−アルコキシ−６，７−ジヒドロ−５−メチル−９−フルオロ−１−オキソ−１Ｈ，５Ｈ−ベンゾ〔ｉｊ〕キノリジン−２−カルボン酸
FI79836B (fi)	1989-11-30	Foerfarande foer framstaellning av en farmaceutiskt aktiv n,n-di-n-propyl-4-hydroxi-3-metansulfonamidofenetylamin
JPH02503670A (ja)	1990-11-01	１，２，３，４，１０，１４ｂ‐ヘキサヒドロジベンゾ〔ｃ，ｆ〕ピラジノ〔１，２‐ａ〕アゼピノ誘導体及び１０‐アザ，１０‐オキサ及び１０‐チア類似体
DE69215482T2 (de)	1997-04-30	2,2'-Alkylendiindolderivate, Verfahren zu ihrer Herstellung, sie enthaltende Arzneimittel und deren Verwendung als Ulcustherapeutikum
JP5486008B2 (ja)	2014-05-07	１‐ブチル‐２‐ヒドロキシアラルキルピペラジン誘導体およびその抗鬱剤としての使用
FR2618436A1 (fr)	1989-01-27	Derives de piperidine, leur preparation et leur application en therapeutique
CZ173294A3 (en)	1995-02-15	Alkyl derivatives of trazodone, process of their preparation and pharmaceutical composition containing thereof and its use
JP7506415B2 (ja)	2024-06-26	Ｖａｎｉｎ－１阻害剤
LU83713A1 (fr)	1982-05-07	Derives de la pyrimidine,leur procede de preparation et les compositions pharmaceutiques les contenant
JPH11506470A (ja)	1999-06-08	新規複素環式化合物
US6593340B1 (en)	2003-07-15	Pharmaceutical compositions containing N-propargylphentermine and related analogs to treat neurodegeneration and/or depression
EP0151052B1 (fr)	1988-03-09	Aminoéthylimidazole, composition pharmaceutique en contenant et procédé de préparation